For a field built on the idea that aging is the biggest upstream driver of chronic disease, the obvious commercial question is also the most frustrating one: if the biology is real, why can’t a company simply develop a drug for “aging”? The short answer is that modern drug regulation is not built to approve existential states. It is built to approve products for specific indications, in specific populations, with endpoints that show a clear benefit. A 2025 scoping review of gerotherapeutic regulation concluded that the FDA, EMA, and Health Canada do not classify aging as a disease, and that current approval systems remain structured around disease-specific therapies rather than interventions aimed at aging as a systemic biological process.
That does not mean regulators think aging biology is nonsense. It means there is a category mismatch between how geroscience describes the problem and how regulators license products. The FDA’s own framework for surrogate endpoints makes the logic clear: a biomarker or surrogate can support approval only when it is expected to predict a real clinical benefit, meaning how a patient feels, functions, or survives. In aging, that bridge is still weak. The 2023 Cell biomarker framework noted that no aging biomarkers of any category have yet been approved by U.S. regulators for clinical applications, and that aging-relevant functional measures are not currently included in the FDA’s table of surrogate endpoints used as the basis of approval.
So the central problem is not merely philosophical. It is operational. Aging is diffuse, gradual, heterogeneous, and universal. It unfolds across organs, tissues, and functions at different speeds in different people. A regulator, by contrast, has to ask a much narrower set of questions: what exactly is the treated condition, who qualifies for treatment, what is the primary endpoint, and what evidence shows that the intervention produces meaningful benefit rather than an interesting biological signal? Those are sensible questions. They are also the reason aging still sits awkwardly inside existing approval systems.
The issue is not that aging is irrelevant to medicine
In fact, the scientific case for targeting aging has only grown stronger. Recent geroscience reviews argue that aging is more than the accumulation of named diseases; it also drives frailty, loss of resilience, disability, and functional decline. The same literature makes another important point: interventions informed by the hallmarks of aging may either slow multiple diseases at once or suggest new ways of treating specific diseases more effectively. That second route matters, because it is much easier to regulate. A 2025 JCI review noted explicitly that geroscience-informed approaches are already being used in disease-specific settings such as HFpEF and Alzheimer’s disease.
That distinction helps explain the current regulatory stalemate. Regulators are not saying, “You may not use aging biology.” They are effectively saying, “Bring that biology to us in a form we know how to evaluate.” In practice, that usually means a disease indication, a function-related indication, or an outcome bundle that can be defended clinically. The deeper the field’s biology becomes, the more obvious this becomes: the first approved gerotherapeutics may not arrive labeled as anti-aging products at all. They may arrive as therapies for age-related conditions that happen to be unusually upstream in their mechanism.
Why the label still stops short of “aging”
One reason is classification. The 2025 scoping review argued that formal recognition of aging as a treatable condition remains politically and ethically contested, partly because an indication for aging per se risks pathologizing older adults and intensifying ageist assumptions. Even setting that aside, the review found that the absence of aging as a recognized indication limits the development of standardized endpoints and regulatory pathways. In plain language: if the category is unstable, the trial design becomes unstable too.
A second reason is endpoints. Mortality is the cleanest theoretical endpoint for a longevity drug, but it is usually impractical because trials would have to be large, long, and expensive. Biomarkers look like the obvious shortcut, yet the field is not there. A 2025 Delphi-style consensus paper on geroscience endpoints found agreement that outcome measures should include multiple dimensions of health — disease, function, and patient-reported outcomes — and that blood-based biomarkers were unlikely to be accepted as primary endpoints of efficacy trials. A 2024 Nature Medicine review added that there are still no recommended FDA or EMA guidelines for standardizing the development, measurement, or validation of aging biomarkers.
A third reason is commercial. The scoping review noted that repurposed drugs such as metformin may be scientifically attractive but commercially awkward, because even if they affect aging biology, they still need to prove aging-relevant outcomes and often do not come with fresh regulatory exclusivity. That makes capital formation harder and pushes companies toward indications with clearer approval logic and better reimbursement prospects. In other words, the regulatory problem quickly becomes a financing problem.
So what do longevity startups do instead?
They do not wait for the world to hand them an “aging” label. They route around it.
1) They target specific age-related diseases
This is the cleanest and most conventional strategy. Rather than asking regulators to bless “aging,” companies choose diseases or conditions whose incidence rises sharply with age and whose endpoints are already legible to medicine — Alzheimer’s disease, heart failure, mobility decline, frailty-linked dysfunction, inflammatory conditions, or organ-specific degeneration. A 2023 review on geroscience trials described exactly this landscape: some studies focus on clusters of diseases, but others target specific age-related diseases such as Alzheimer’s or conditions such as loss of mobility, delirium, immunosenescence, or loss of intrinsic capacity.
This approach can look less revolutionary than the marketing decks suggest, but it is often much smarter. It lets a company use geroscience as the mechanistic rationale while asking regulators a question they already understand. The JCI review made this logic explicit when it argued that interventions informed by aging biology may support disease-specific therapy and prevention even before the field wins recognition for aging itself as an indication.
2) They use composite healthspan or multimorbidity endpoints
The most famous example is TAME, not because it solved the problem, but because it showed what a workaround looks like. The TAME design was developed in consultation with the FDA and built around a composite primary endpoint: the incidence of major age-related chronic diseases plus death, with additional attention to physical and cognitive function. In other words, it does not ask regulators to approve “aging” as a mystical category. It asks whether one intervention can delay several concrete bad outcomes that tend to travel with aging.
That is a meaningful difference. Composite endpoints remain imperfect and require careful interpretation, but they translate the geroscience hypothesis into something closer to standard clinical trial logic. The current literature repeatedly treats TAME as the clearest precedent for how aging biology might be tested without first winning a formal aging indication. That is why it matters so much to investors and founders even though it is not, by itself, a regulatory revolution.
3) They run biomarker-heavy early trials while staying modest about the label
This is probably the most important operational strategy in the sector today. The 2025 recommendations paper on longevity biotechnology companies argued that biomarkers of aging can help stratify participants, prioritize interventions, and monitor responses, even though no biomarker of aging has yet been clinically validated as a regulatory endpoint. The idea is not to win an anti-aging label tomorrow. It is to accumulate standardized samples, wearable data, and longitudinal outcomes now so that validation becomes possible later.
That is also why so many early-stage longevity programs feel half like therapeutics companies and half like data companies. In a field where the endpoint problem remains unresolved, biomarker collection is not cosmetic. It is part of the asset. A company that can show a therapy moved plausible aging biomarkers, while also linking those shifts to function or disease outcomes, is building both a clinical program and a validation dataset. The 2023 biomarker framework and 2024 validation review both argue that this kind of careful, context-specific validation is essential if aging biomarkers are ever going to support real clinical translation.
4) They soften the claim and sell around the edges
This is the consumer route: supplements, diagnostics, cosmetics, memberships, and “wellness” offerings that avoid direct disease claims while still trading on longevity language. The FDA’s structure/function framework explains why this route is attractive. Dietary supplements can make certain structure/function or general well-being claims without pre-approval, as long as the firm has substantiation, notifies the FDA where required, and includes the disclaimer that the product is not intended to diagnose, treat, cure, or prevent any disease. That is a real business path — but it is not a drug approval path.
The same boundary exists in cosmetics. FDA states that products marketed as cosmetics do not need premarket approval, but if they claim to affect the structure or function of the body — for example by removing wrinkles or increasing collagen production — they become drugs or devices under the law. That is why so much “anti-aging” marketing ends up sounding oddly careful: firms want the aura of medical efficacy without stepping fully into drug territory.
5) Some drift into the grey zone and get hit
This is where the field becomes less elegant. FDA’s July 2025 advisory letter to Aardsma Research & Publishing said its product “Dr. Aardsma’s Anti-Aging Vitamins” was being marketed with claims suggesting treatment or prevention of diseases such as prostate cancer, non-Hodgkin’s lymphoma, macular degeneration, and hypertension, and therefore constituted an unapproved new drug. Likewise, FDA’s February 2026 warning letter to Dynamic Stem Cell Therapy said the company was marketing an umbilical-cord-derived stem-cell product as an unapproved new drug and unlicensed biologic. These are not edge cases in the abstract. They are reminders that once a longevity company crosses from suggestive wellness language into disease or structure/function claims without the right evidentiary and regulatory footing, the enforcement logic hardens quickly.
The real regulatory story
So why do regulators still not approve “aging”? Not because the biology is unserious, and not because every agency is asleep. The harder answer is that modern regulation needs a defined context of use, a credible endpoint, and a benefit that can be explained in clinical terms. Aging, as a master risk factor that expresses itself differently across people and organs, does not yet fit neatly into that framework. The biomarker field is advancing, but even the field’s own consensus documents emphasize that validation is incomplete and that no aging biomarkers have yet crossed into approved clinical use.
That is why the smartest longevity startups are not waiting for a pristine anti-aging pathway to appear. They are choosing disease indications, building composite healthspan logic, collecting biomarker-rich datasets, and, in some cases, operating in consumer categories that are commercially real but scientifically easier to overstate. The first true regulatory win for geroscience is unlikely to arrive in a bottle labeled “aging.” It is more likely to arrive disguised as something the system already knows how to approve — a therapy for a major age-related condition, a validated composite prevention strategy, or eventually a function- and biomarker-linked intervention that proves it can change how people actually age.